Study guide
14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
Certified Nuclear Medicine Technologist CNMT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CNMT Exam Facts 1.2 How to Use This Guide
2 Radiation Physics Fundamentals
2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles
3 Biological Effects & ALARA
3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring
4 NRC & Regulatory Compliance
4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records
5 Generators & Kit Preparation
5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control
6 Tc-99m Diagnostic Agents
6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells
7 Non-Tc Diagnostic & PET Agents
7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents
8 Therapeutics, Adjuncts & Administration
8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents
9 Non-Imaging Instrumentation
9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment
10 Imaging Systems & Quality Control
10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization
11 Pulmonary, Bone, Oncology & Infection Imaging
11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures
12 Renal, Endocrine & Hematopoietic Imaging
12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique
13 Cardiovascular Procedures
13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing
14 GI, CNS, Therapy & Hybrid CT Procedures
14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
15 Patient Care & Clinical Workflow
15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis
14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
Key Takeaways Explain This Topic AI
Radionuclide cisternography uses about 0.5 mCi of preservative-free In-111 DTPA injected intrathecally by a credentialed physician, imaged with a medium-energy collimator and dual windows on the 171 and 245 keV photopeaks.
Normal cisternography shows activity ascending over the cerebral convexities by about 24 hours with no persistent ventricular reflux; early ventricular reflux that persists at 24–48 hours with delayed convexity clearance is the communicating-hydrocephalus pattern.
For suspected CSF rhinorrhea or otorrhea, ENT places weighed pledgets before injection; pledgets and a simultaneous serum sample are counted in a well counter, and a pledget-to-serum activity ratio below about 1.3 is normal while roughly 1.5 or greater supports a leak.
Shunt patency studies inject a small activity of Tc-99m DTPA or pertechnetate into the shunt reservoir under strict aseptic technique, then image proximal reflux and distal flow to distinguish proximal from distal obstruction.
Only preservative-free, sterile, pyrogen-free formulations may be given intrathecally, and the technologist verifies the product, route, and patient before the physician injects.
Last updated: August 2026
14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
Quick Answer: In-111 DTPA (~0.5 mCi), preservative-free, intrathecal , imaged with a medium-energy collimator and dual windows at 171 and 245 keV . Normal = convexity flow by 24 h , no persistent ventricular reflux. Leak = pledget-to-serum ratio ≥ ~1.5 . Shunt = inject the reservoir , watch proximal reflux and distal clearance.
Section 14.2 named these studies inside the broader CNS chapter. The blueprint lists cisternogram , CSF leak , and CSF shunt patency as three separate procedures, and each has technique that can invalidate the result.
Why In-111 DTPA
- Property Consequence
- Half-life ≈ 2.8 days Supports imaging out to 24, 48, and 72 hours , which the slow CSF circulation requires
- Photopeaks 171 and 245 keV Medium-energy collimator ; set dual windows (about ±10% each) and add the counts
DTPA chelate Stays in the CSF space, is not absorbed into brain tissue, and clears by arachnoid granulations into blood
Formulation Must be preservative-free, sterile, and pyrogen-free for intrathecal administration
The absolute rule: an intrathecal injection is the highest-consequence route in the department. The technologist independently verifies the product name, formulation, activity, expiration, patient identity, and the ordered route before handing the syringe to the physician performing the lumbar puncture. Never substitute a multi-dose vial containing preservative.
Radionuclide Cisternography
Indications: normal-pressure hydrocephalus evaluation, CSF flow dynamics, shunt or reservoir function questions, and CSF leak workups.
- Step Practice
- Activity About 0.5 mCi (≈18.5 MBq) In-111 DTPA intrathecally by lumbar puncture
- Post-injection care Patient often lies flat for a defined period per the physician; watch for post-LP headache
- Imaging times Commonly 2–4 h , 6 h , 24 h , and often 48 and 72 h
- Views Anterior, posterior, and both laterals of the head; add spine views when a spinal leak is suspected
- Counts/time Fixed time per view so serial images are comparable
- Pattern Recognition
- Time Normal Communicating (normal-pressure) hydrocephalus pattern
- 2–4 h Activity in basal cisterns Basal cisterns plus early ventricular reflux
24 h Activity over the cerebral convexities , ventricles clear Persistent ventricular activity , delayed or absent convexity flow
48–72 h Progressive clearance Continued ventricular retention
Transient ventricular reflux that clears by 24 hours can be a normal variant — persistence is the abnormal finding.
CSF Leak Localization with Pledgets
Used for suspected rhinorrhea (nasal) or otorrhea (aural) leaks.
Step Practice
1. Weigh and label pledgets ENT places sized pledgets (roughly 1 cm², absorbent) in defined nasal or aural positions; record left/right and site meticulously
- 2. Inject In-111 DTPA intrathecally Same activity and technique as cisternography
- 3. Image Serial head and, when indicated, spine images at the protocol times
- 4. Remove pledgets at the protocol interval Place each in a separate, labeled, pre-weighed counting tube
- 5. Draw a simultaneous blood sample Usually about 5 mL into a heparinized tube; separate serum or plasma
- 6. Count in a NaI well counter Same geometry, same count time, background corrected
- 7. Compute the ratio Activity per gram of pledget divided by activity per gram (or mL) of serum
- Ratio Interpretation (laboratory-specific)
- < ~1.3 Normal — activity is explained by blood-pool background
- ≥ ~1.5 Supports an active CSF leak at that site
Failure modes: mislabeled or swapped pledgets, pledgets left in the wrong position, blood contamination of the pledget from the placement trauma, drying and weight loss before counting, and forgetting the serum sample entirely — without the denominator there is no result.
Shunt Patency Studies
Question: is a ventriculoperitoneal (or ventriculoatrial/ventriculopleural) shunt flowing, and if not, is the obstruction proximal (ventricular catheter) or distal (peritoneal end)?
Step Practice
Access Physician accesses the shunt reservoir with a small needle under strict aseptic technique , often after skin prep and hair clipping
Agent A small activity (roughly 0.5–1 mCi class) of Tc-99m DTPA or pertechnetate , preservative-free
Proximal limb With the distal limb manually occluded, look for reflux into the ventricles — reflux indicates a patent proximal catheter
Distal limb Release the occlusion and acquire dynamic images: prompt flow down the tubing and spillage into the peritoneal cavity indicates a patent distal limb
Quantitation Time–activity curve over the reservoir or ventricles; a prolonged clearance half-time suggests distal obstruction
Delayed views Often at 30 minutes to a few hours to confirm peritoneal distribution
Findings map: ventricular reflux present + no distal flow → distal obstruction . No ventricular reflux + normal distal flow → proximal obstruction . Neither → total occlusion or a technical access failure. Sluggish everything with a slow curve → partial obstruction.
Radiation and infection safety: this is a sterile CNS procedure. Prepare the dose aseptically, keep the field sterile, use the smallest volume the protocol allows, and document the reservoir accessed.
Comparison Table
- Study Route and agent Key measurement
- Cisternography Intrathecal In-111 DTPA ~0.5 mCi Convexity flow by 24 h vs persistent ventricular reflux
- CSF leak Intrathecal In-111 DTPA + nasal/aural pledgets Pledget-to-serum ratio (≥ ~1.5 positive)
Shunt patency Reservoir injection of Tc-99m DTPA/pertechnetate Proximal reflux and distal peritoneal spill; clearance half-time
Bottom line: verify the route and the formulation, count the pledgets against a serum sample, and describe shunt findings in terms of proximal versus distal limbs.